Explained — Why Natco Pharma shares surged up to 5% on Friday

The latest ruling clears the path for Natco to launch its generic version of the drug used in the treatment of Spinal Muscular Atrophy immediately.

Leave a Reply

Your email address will not be published. Required fields are marked *